ICSE 2020
วันที่ 13 - 15 ตุลาคม 2563
ณ Fiera Milano, Italy
The demand for outsourced manufacturing continues to increase, driven by pharma’s desire for cost efficiency. In addition, efforts to streamline and shed in-house capacity means some drug companies now have no option but to outsource.
- There is a lack of biopharma outsourcing capacity - particularly the skills required for cell and gene therapy production. This represents a real opportunity for CDMOs willing to invest in the expertise and technical capacity required to undertake such projects. Skills in viral vector production are in particular demand.
- Demand for biopharma capacity is also driving the development of technical solutions. Accessing these technologies will be critical for all CDMOs interested in capturing market share.
- It is also important that CDMOs are able to add expertise in line with innovation in drug development.
- Finding skilled staff is a global challenge. It is important that CDMO hiring strategies focus on emphasising the range of work undertaken and their technical capabilities in order to attract top talent.
ลงทะเบียน
ไทย
